Does that mean there will be 125 opportunities to profit?
Actually, there s much more. Each one of these drugs must pass through Phase II and Phase III clinical trials, and each time they do, it s a huge milestone for the drug and a boon for the company. And each time one of these milestones is reached, word has a way of “leaking” out before the official announcement. That s when the mysterious volume spikes occur. And that s when our opportunity to profit comes. Something else. Another reason why Biotech is the next wave is because there has never been a more favorable FDA environment when it comes to approving new drugs quickly. Once a bastion of inefficiency and red tape, the FDA s approval process has become much more streamlined and much more interested in seeing that these worthwhile drugs are brought to market in a timely fashion. Also, believe it or not, biotech companies are still tremendously undervalued. In fact, the market cap of all the major players in the biotechnology sector put together is less than that of Microsoft s! But t
